Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jane Griffiths

- PMLiVE

Boehringer to move psoriasis programme into phase III

Candidate outperformed J&J’s rival Stelara 

- PMLiVE

Galapagos and Janssen end inflammation alliance

Galapagos regains right to GLPG1690

- PMLiVE

Stelara outlook promising for psoriatic arthritis

Likely to be recommended alone and in combination with methotrexate

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

Making the right mobile health choices

Creative thinking is one of the requirements to ensure lasting healthcare change

- PMLiVE

Apple launches new research software programme

Tech firm made the announcement during the promotion of its new smart watch

- PMLiVE

Digital health charge led by millennials in the US

But older patients more likely to use pharma sites if directed by a doctor

- PMLiVE

AbbVie to acquire cancer biopharma Pharmacyclics for $21bn

Comes six months after the US firm pulled out of a $54bn deal with Shire

- PMLiVE

Healthcare boundaries ‘being erased,’ says PwC

Reports claims technology is eradicating person-to-person interaction

- PMLiVE

Boehringer steals lead among NOACs with Pradaxa antidote

Has filed reversal agent for European approval

- PMLiVE

Sanofi joins WHO-backed diabetes mHealth programme

Becomessole pharma partner for Be Healthy, Be Mobile's diabetes arm

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links